Investing in our Long-Term Growth

The Exact Sciences team highlighted the enormous strides we’re making toward our mission of eradicating colon cancer when we recently released preliminary fourth quarter and full-year 2017 results. During the year, approximately 571,000 Cologuard tests were completed, a year-over-year increase of 134 percent. Nearly 11,000 health care providers ordered Cologuard for the first time during the fourth quarter of 2017. The total number of providers who have ordered Cologuard since its launch increased to nearly 102,000.

Read More

Topics: Company

Expansion through the Third Quarter

Today Exact Sciences released earnings for the third quarter of 2017. Results exceeded our expectations with revenue of $72.6 million, up 26% from the second quarter, and 161,000 completed Cologuard tests, up 19% from the second quarter.

Read More

Topics: Company

A Strong Start to 2017

Exact Sciences recently announced our first quarter 2017 financial results, highlighting the accelerating growth trajectory for Cologuard.  Beyond the headline-making news, we continue to see a large market opportunity for Cologuard. While changing the standard of care will take time and investment in our infrastructure, we have never been more confident in the long-term growth of Cologuard and Exact Sciences.  

Read More

Topics: Company